Iovance Biotherapeutics Inc. Stock
We can see a decrease in the price for Iovance Biotherapeutics Inc.. Compared to yesterday it has lost -€0.080 (-1.370%).
With 8 Buy predictions and not the single Sell prediction the community is currently very high on Iovance Biotherapeutics Inc..
With a target price of 11 € there is a hugely positive potential of 91.3% for Iovance Biotherapeutics Inc. compared to the current price of 5.75 €.
So far the community has only identified positive things for Iovance Biotherapeutics Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Iovance Biotherapeutics Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Iovance Biotherapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics Inc. | -1.370% | 56.091% | 57.143% | 203.172% | 145.784% | -9.668% | -69.121% |
| Ligand Pharmaceuticals | 1.560% | -4.580% | -9.420% | 96.850% | 50.602% | 296.825% | 166.923% |
| United Therapeutics | 1.280% | -1.202% | -7.386% | 71.854% | 3.885% | 104.280% | 153.657% |
| Ionis Pharmaceuticals Inc. | 1.690% | 4.583% | -3.842% | 38.314% | -27.810% | 35.338% | 46.404% |
Comments
Iovance Biotherapeutics (IOVA) had its price target lowered by Chardan Capital from $16.00 to $14.00. They now have a "buy" rating on the stock.
Show more
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics (IOVA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $16.00 price target on the stock.
Show more
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics (IOVA) had its price target raised by Barclays PLC from $10.00 to $11.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for IOVA provided by MarketBeat


